Colder's new genderless AseptiQuik® G Connectors make single-use sterile connections faster, easier and safer—even in non-sterile conditions. Universal mating simplifies systems integration, increases process flexibility and minimizes operator error.
Universal sterile connectors simplify single-use systems integration
New genderless AseptiQuik® G Connectors from Colder Products Company make single-use sterile connections faster, easier and safer than ever before—even in non-sterile conditions.
The genderless design eliminates separate male and female components, allowing any G series connectors to mate together. This universal “G” mating simplifies systems integration and increases process flexibility for transferring valuable media.
The unique design of AseptiQuik G connectors minimizes the risk of operator error, reduces complexity, labor and inventory requirements. The new G series is available in a full range of interchangeable 1/4” to 3/4” flow solutions, in both gamma and high-temperature versions. Terminations include 1/4” hose barb, 1/2” hose barb, 3/4” hose barb and 3/4” sanitary.
The AseptiQuik family of connectors—in a full range of 1/8” to 1” flow configurations—provides unequalled ease of use and robust construction for reliable, repeatable performance without burdensome assembly aids, clamps or tube welding. AseptiQuik connectors are ideal for single-use bag and tubing assemblies, bioreactors, mixers, sampling and filling applications. For applications where reliability and sterility are a must, Connect with Colder.
See how easy connections are with AseptiQuik® G — click here for video.
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERY
February 14th 2025Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering greater patient comfort and adherence to expand the therapeutic market.